Postpartum hemorrhage, severe bleeding after childbirth, is a leading cause of maternal mortality around the world. But many of these deaths can be prevented—and a real-time blood-monitoring technology called viscoelastic testing (VET) could play a crucial role. Though used in parts of Europe, VET is not yet a standard part of maternity care in the United States. A new sweeping review from the Southern California Evidence Review Center, part of the Keck School of Medicine of USC, brings U.S. hospitals a step closer to improving treatment of maternal hemorrhage with VET. The study, just published in the International Journal of Obstetric Anesthesia, includes a summary of findings from 156 research publications. The study was commissioned by the Patient-Centered Outcomes Research Institute (PCORI) and included interviews with patients, clinicians and policymakers. The review revealed that VET holds promise, but that high-quality research on its use for maternity care is limited. A major takeaway is the need for a large-scale, U.S.-based research study to test VET’s effectiveness in this context, as well as a broader professional consensus about when and how the technology should be applied. Insights from the report can help guide policy, research priorities and other key decisions around the use of this technology.